KIR2DL3 and breast cancer: Besides, although BC patients with the KIR2DL3/C1 interaction treated with BCG did not show differences in the progression-free survival curves, they showed longer 75p-OS times than those without this interaction (71.0 ± 12.0 vs. 56.0 ± 11.0 months, p = 0.031).